Table 1 Relationship between clinical parameters and IFI44L expression in hepatocellular patients
IFI44L | ||||
|---|---|---|---|---|
Variables | N | Low | High | p-value |
Age (years) | ||||
  < 65 | 100 | 49 (49%) | 51 (51%) | 0.892 |
 ≧65 | 117 | 56 (48%) | 61 (52%) | |
Gender | ||||
 Female | 58 | 35 (60%) | 23 (40%) | 0.306 |
 Male | 159 | 75 (47%) | 84 (53%) | |
Differentiation | ||||
 Well | 12 | 3 (25%) | 9 (75%) | 0.892 |
 Moderate | 105 | 55 (52%) | 50 (48%) | |
 Poor | 94 | 47 (50%) | 47 (50%) | |
 Undifferentiation | 6 | 1 (17%) | 5 (83%) | |
Stage | ||||
 I, II | 180 | 84 (47%) | 96 (53%) | 0.029 |
 III, IV | 37 | 25 (68%) | 12 (32%) | |
Hepatitis B surface antigen | ||||
 Negative | 106 | 52 (49%) | 54 (51%) | 0.892 |
 Positive | 111 | 56 (51%) | 55 (49%) | |
Hepatits C virus | ||||
 Negative | 150 | 74 (49%) | 76 (51%) | 0.883 |
 Positive | 67 | 34 (51%) | 33 (49%) | |
Tumor Number | ||||
 Single | 177 | 87 (49%) | 90 (51%) | 0.841 |
 Multiple | 40 | 21 (53%) | 19 (47%) | |
Tumor size | ||||
  < 5 cm | 140 | 59 (42%) | 81 (58%) | 0.002 |
 ≧5 cm | 77 | 49 (64%) | 28 (36%) | |
Relapse | ||||
 - | 196 | 91 (46%) | 105 (54%) | 0.002 |
 + | 21 | 17 (81%) | 4 (19%) | |